Arthneeti
ML

Morepen Laboratories Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Morepen Laboratories Ltd Q3 FY26 Results & Presentation Highlights: Revenue, Margins & Order Book

Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.

Price₹117
Market cap₹6.6K Cr
P/E56.4
Updated25 Sept 2026
Read3 min read

Based on Morepen Laboratories Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q3 FY26 consolidated gross revenue: Rs. Quarterly EBITDA (Consolidated) Q3 FY26: Rs.

From Morepen Laboratories Ltd's Q3 FY26 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Q3 FY26 consolidated gross revenue: Rs. 488 crores, up 17% from Q3 FY25 Rs. 416 crores (Page 23).
  • Q3 FY26 standalone gross revenue: Rs. 462 crores, up 23% from Q3 FY25 Rs. 374 crores (Page 22).
  • Medical Devices revenue Q3 FY26: Rs. 78 crores vs Rs. 73 crores in Q3 FY25, 6% growth (Page 19).
  • BP Monitor revenue and other medical devices segments increased significantly, e.g., BP monitors 17.4% share (Page 20).
  • Pharma business (API + formulations) Q3 FY26 revenue: Rs. 767 crores nearly flat vs Rs. 791 crores in Q3 FY25, slight 3% decline (Page 9).

2 more points management made on revenue & sales performance

Profitability & Margins

See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The investor presentation does not explicitly describe any specific capex, capacity expansion, or new plant/project details including amounts, status, or timelines. The available pages focus primarily on financial performance, revenue segments, product-wise breakups, and standard disclaimers. There are no clear mentions or data related to capital expenditure plans or capacity expansion initiatives within the text or charts provided in this presentation.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided investor presentation (pages 1-24) does not explicitly mention, report, or provide data on order book, order inflow, or pending orders for Morepen Laboratories Limited. The presentation primarily focuses on: - Quarterly and nine-month financial performance (gross revenue, EBITDA, PAT) for FY26 Q2 and Q3. - Segment-wise and product-wise revenue breakup (Pharma business - API and formulations, Medical Devices - glucose monitors, BP monitors, thermometers, nebulisers, pregnancy kits, ortho supports). - Growth percentages and standalone vs consolidated financial figures.

2 more points management made on order book & pipeline

Morepen Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹485 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Morepen Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmova Ltd (Q3 FY26)

    2,143 Cr., up from Rs. Key investor presentation takeaways from Jubilant Pharmova Ltd's Q3 FY26 investor presentation — and how it ranks against sector peers.

  • NGL Fine Chem Ltd (Q3 FY26)

    Quarterly Revenue (Q3FY26):** ₹127.51 crores . Key investor presentation takeaways from NGL Fine Chem Ltd's Q3 FY26 investor presentation — and how it ranks aga

  • Shree Ganesh Remedies Ltd (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹21.11 Cr . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q3 FY26 investor presentation — and how it rank

  • Anuh Pharma Ltd (Q3 FY26)

    Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr) . Key investor presentation takeaw

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Morepen Laboratories Ltd Q3 FY26 results?

Q3 FY26 consolidated gross revenue: Rs. Quarterly EBITDA (Consolidated) Q3 FY26: Rs.

What is Morepen Laboratories Ltd share price analysis?

Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 56.4 with a market cap of ₹6,625 Cr. Investors should review the full earnings analysis for detailed insights.

Is Morepen Laboratories Ltd planning capital expenditure?

The investor presentation does not explicitly describe any specific capex, capacity expansion, or new plant/project details including amounts, status, or timelines.

Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.